Lim Soo-Jeong, Lee Mi-Kyung, Kim Chong-Kook
Research Institute, National Cancer Center, Goyang, Gyeonggi, Korea.
J Control Release. 2004 Nov 5;100(1):53-61. doi: 10.1016/j.jconrel.2004.07.032.
The principal aim of this study was to investigate whether the solid lipid nanoparticle (SLN) powder formulation of all-trans retinoic acid (ATRA) can favorably alter the chemical stability and biological activities of ATRA. SLN powder formulation of ATRA was obtained by freeze-drying of SLN dispersions. The chemical stability of ATRA was determined by HPLC analysis. The anticancer efficacy of ATRA was determined by evaluating antiproliferative effects of ATRA on cancer cell lines. Hemolytic potential of ATRA was spectrophotometrically determined after incubation with red blood cells (RBCs) in vitro. ATRA could be efficiently incorporated in SLN powder without impairing the physical stability of lipid nanoparticles. After 3 months of storage, >90% ATRA remained intact in SLN powder, indicating that the chemical stability of ATRA was substantially improved by incorporation in SLN powder. The antiproliferative effects of SLN powder formulation of ATRA on a wide range of cancer cell lines were not significantly different from that of free ATRA. Furthermore, the incorporation of ATRA in SLN powder significantly reduced the hemolytic potential of ATRA. Taken together, the molecular characteristics that currently appear to limit the clinical efficacy of ATRA were greatly improved by preparing SLN powder formulation. SLN powder formulation of ATRA may have a potential in enhancing the efficacy of ATRA in cancer chemoprevention and therapeutics.
本研究的主要目的是调查全反式维甲酸(ATRA)的固体脂质纳米粒(SLN)粉末制剂是否能有利地改变ATRA的化学稳定性和生物学活性。ATRA的SLN粉末制剂通过SLN分散体的冷冻干燥获得。通过高效液相色谱(HPLC)分析测定ATRA的化学稳定性。通过评估ATRA对癌细胞系的抗增殖作用来确定ATRA的抗癌功效。在体外与红细胞(RBC)孵育后,通过分光光度法测定ATRA的溶血潜力。ATRA可以有效地掺入SLN粉末中,而不会损害脂质纳米粒的物理稳定性。储存3个月后,>90%的ATRA在SLN粉末中保持完整,这表明通过掺入SLN粉末,ATRA的化学稳定性得到了显著改善。ATRA的SLN粉末制剂对多种癌细胞系的抗增殖作用与游离ATRA的抗增殖作用没有显著差异。此外,ATRA掺入SLN粉末中显著降低了ATRA的溶血潜力。综上所述,通过制备SLN粉末制剂,目前似乎限制ATRA临床疗效的分子特性得到了极大改善。ATRA的SLN粉末制剂在提高ATRA在癌症化学预防和治疗中的疗效方面可能具有潜力。